– USA, MA – Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately.
“We are delighted to welcome Jesper to our Board of Directors,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “He is a highly accomplished executive with current management experience as President and CEO of Radius Health, a biopharmaceutical company, and previously served as President and Executive Vice President, Novo Nordisk Inc. USA, where his expertise in product launches and management were instrumental in growing Novo to become the 15th largest pharmaceutical company worldwide. Jesper also brings extensive pharmaceutical commercialization expertise, which will broaden and strengthen the overall skills of our Board as we advance our pipeline of innovative medicines towards regulatory approval.”
Dr Jesper Høiland
Mr. Høiland is an industry veteran with more than 30 years of experience in the biopharmaceutical industry across numerous senior leadership roles, geographies and therapeutic areas. As President and Chief Executive Officer of Radius Health, Inc., Mr. Høiland successfully launched Radius’ first commercial product, TYMLOS™. Prior to joining Radius, Mr. Høiland served as President and Executive Vice President of Novo Nordisk. During his more than 20-year tenure at Novo Nordisk, Mr. Høiland held multiple global roles of increasing responsibility, including leading its International Operations which spanned 150 countries. Mr. Høiland is a member of the Board of Directors of LEO Pharma and from 2014-2016 was a Board member of PhRMA, the Pharmaceutical Research and Manufacturers of America.
“Concert’s pipeline has significant potential to meaningfully impact patients affected by serious diseases that have unmet medical needs,” said Mr. Høiland. “I am excited to join the Board and look forward to sharing my insights and experiences as Concert’s product candidates, CTP-543 for alopecia areata and CTP-692 for schizophrenia, advance through development toward commercialization.”
Mr. Høiland received his M.Sc. in Management from Copenhagen Business School in Denmark.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems disorders.
For more information: https://www.concertpharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
